5. Conclusion
The use of FGF21 analogs reduced serum triglyceride levels, LDL levels, PRO-C3 levels, and glycated hemoglobin while increasing HDL levels. Despite no significant differences in NASH resolution and weight loss between the FGF21 analog-treated group and the control group, these findings suggest a potential dual benefit of FGF21 in liver health and glycemic control. We emphasize the need for larger RCTs and do not support the routine use of FGF21 analogs in all patients with NASH. Instead, FGF21 analogs may be reasonable among selected low stages of fibrosis and NASH disease, at the discretion of clinicians and patients through shared decision-making based on individualized considerations of treatment risks and benefits.